Hepatitis B Annual
Home

Current Issue  

Back Issues   

Instructions   

Search Reader Login   Users online: 265 Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
>>> Ahead of Print <<<
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   2004| January-December  | Volume 1 | Issue 1  
 
 
  Archives   Next Issue   Most popular articles   Most cited articles
 
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
REVIEW ARTICLE
HBV and Indian medical and dental students
Shivaram Prasad Singh, Manorama Swain, Indu Bhusan Kar
January-December 2004, 1(1):229-239
  37,842 605 -
Hepatitis B Immunization: FAQs
Shivaram Prasad Singh
January-December 2004, 1(1):240-248
  31,729 731 -
Approach to the management of an incidentally detected HBsAg carrier
Yogesh Kumar Chawla
January-December 2004, 1(1):210-216
  20,705 1,095 -
Hepatitis B associated hepatocellular carcinoma: Epidemiology, diagnosis and treatment
KM Mohandas
January-December 2004, 1(1):140-152
  18,318 1,346 -
Epidemiology of hepatitis B virus infection in India
Abhijit Chowdhury
January-December 2004, 1(1):17-24
  17,859 1,725 -
Hepatitis B virus infection in pregnancy
Narendra Prasad Bohidar
January-December 2004, 1(1):199-209
  17,133 1,048 -
Hepatitis B virus infection in children in India
Malathi Sathiyasekaran, VS Sankaranarayanan
January-December 2004, 1(1):72-91
  15,575 928 -
Prophylaxis of viral hepatitis: A global perspective
Voranush Chongsrisawat, Pantipa Chatchatee, Yong Poovorawan
January-December 2004, 1(1):25-59
  10,116 563 -
Management of HBV infection in decompensated liver disease
Sudeep Khanna, Arun Kumar
January-December 2004, 1(1):153-198
  9,168 543 -
Universal neonatal hepatitis B virus vaccination in India: Why?
Rakesh Aggarwal
January-December 2004, 1(1):60-71
  8,125 382 -
Histopathological scoring of chronic viral hepatitis
Gupta S Datta
January-December 2004, 1(1):92-112
  7,712 576 -
Management of chronic hepatitis due to hepatitis B virus infection
Subrat Kumar Acharya, Yogesh Batra
January-December 2004, 1(1):113-139
  6,202 495 -
Comments on the prevention of hepatitis B infection in India
Baruch S Blumberg
January-December 2004, 1(1):249-255
  5,731 266 -
Treatment of chronic hepatitis B in HIV patients
Gourdas Choudhuri
January-December 2004, 1(1):217-228
Infection with HIV and HBV often coexist in the same patient as the two viruses share similar modes of transmission. Around 10% of HIV patients are co-infected with HBV. With early diagnosis of HIV infection and effective anti-retroviral treatment leading to improved survival of patients with HIV infection, Hepatitis B related liver disease is emerging as a significant health problem in this group of patients. Acute Hepatitis B tends to become chronic more often in HIV patients (80% vs 10% in HIV uninfected) indicating an immune dysfunction and defective clearance of the virus. Protection against HBV infection should be provided to HIV patients by effective use of Hepatitis B vaccine. Higher and frequent doses may be required in HIV patients as their immune response rates are poor. The response to treatment of CHB with Interferon-alpha in HIV patients is around 0-10%, much less than what is achieved in non-HIV patients. Considering the cost, adverse effects and the poor response with Interferon-alpha, there is lack of optimism vis-a-vis its use in HIV patients. The nucleoside analogue, Lamivudine, has shown promise in this group of patients. Lamivudine is useful in suppressing replication of both HIV and HBV. It has been found to be effective in suppressing HBV replication in 96% of HIV patients with chronic Hepatitis B infection. This was associated with clinical, biochemical and histological improvement in liver function. The dose of Lamivudine required in this special group is higher (300 mg/day), and the duration of treatment is long (until HBe sero-conversion and disappearance of HBV-DNA from blood). Besides, rebound viral replication on discontinuation of treatment and the development of YMDD mutants while on prolonged treatment are major concerns at the moment.
  5,403 294 -
From Australia antigen to eradication programs
Baruch S Blumberg
January-December 2004, 1(1):10-16
  5,191 354 -
EDITORIAL
Editorial
Shivaram Prasad Singh, Yogesh Kumar Chawla
January-December 2004, 1(1):7-9
  3,554 206 -
FOREWORD
Foreword
Baruch S Blumberg
January-December 2004, 1(1):5-6
  2,940 240 -
  The Journal 
  Online Submission 
  Subscribe 
  Advertise 
  Addresses 
  Most Popular Articles 
  My Preferences